1. Academic Validation
  2. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites

A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites

  • Bone. 2010 Jul;47(1):12-22. doi: 10.1016/j.bone.2010.03.006.
Monica M Reinholz 1 Shawn P Zinnen Amylou C Dueck David Dingli Gregory G Reinholz Leslie A Jonart Kathleen A Kitzmann Amy K Bruzek Vivian Negron Abdalla K Abdalla Bonnie K Arendt Anthony J Croatt Luis Sanchez-Perez David P Sebesta Harri Lönnberg Toshiyuki Yoneda Karl A Nath Diane F Jelinek Stephen J Russell James N Ingle Thomas C Spelsberg Henry B F Hal Dixon Alexander Karpeisky Wilma L Lingle
Affiliations

Affiliation

  • 1 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55906, USA. reinholz.monica@mayo.edu
Abstract

Despite palliative treatments, tumor-induced bone disease (TIBD) remains highly debilitating for many Cancer patients and progression typically results in death within two years. Therefore, more effective therapies with enhanced anti-resorptive and cytotoxic characteristics are needed. We developed bisphosphonate-chemotherapeutic conjugates designed to bind bone and hydrolyze, releasing both compounds, thereby targeting both osteoclasts and tumor cells. This study examined the effects of our lead compound, MBC-11 (the anhydride formed between arabinocytidine (AraC)-5'-phosphate and etidronate), on bone tumor burden, bone volume, femur bone mineral density (BMD), and overall survival using two distinct mouse models of TIBD, the 4T1/luc breast Cancer and the KAS-6/1-MIP1alpha multiple myeloma models. In mice orthotopically inoculated with 4T1/luc mouse mammary cells, MBC-11 (0.04 microg/day; s.c.) reduced the incidence of bone metastases to 40% (4/10), compared to 90% (9/10; p=0.057) and 100% (5/5; p=0.04) of PBS- or similarly-dosed, zoledronate-treated mice, respectively. MBC-11 also significantly decreased bone tumor burden compared to PBS- or zoledronate-treated mice (p=0.021, p=0.017, respectively). MBC-11 and zoledronate (0.04 microg/day) significantly increased bone volume by two- and four-fold, respectively, compared to PBS-treated mice (p=0.005, p<0.001, respectively). In mice systemically injected with human multiple myeloma KAS-6/1-MIP1alpha cells, 0.04 and 4.0 microg/day MBC-11 improved femur BMD by 13% and 16%, respectively, compared to PBS (p=0.025, p=0.017, respectively) at 10 weeks post-tumor cell injection and increased mean survival to 95 days compared to 77 days in mice treated with PBS (p=0.047). Similar doses of zoledronate also improved femur BMD (p< or =0.01 vs PBS) and increased mean survival to 86 days, but this was not significantly different than in PBS-treated mice (p=0.53). These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for TIBD.

Figures
Products